News >

Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC

Jason Harris
Published: Monday, Oct 30, 2017

lung cancer
Merck has announced that it has withdrawn its European application for pembrolizumab (Keytruda) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non–small cell lung cancer (NSCLC).

Grade ≥3 treatment-related adverse events (AEs) were experienced by 39% of those in the pembrolizumab arm versus 29% of those treated with chemotherapy alone. The most common grade ≥3 AEs with pembrolizumab plus chemotherapy and chemotherapy alone, respectively, were anemia (12% vs 15%), neutrophil count decrease (7% vs 3%), fatigue (3% vs 0%), nausea (2% vs 0%), rash (2% vs 0%), vomiting (2% vs 0%), aspartate aminotransferase increase (2% vs 2%), and alanine aminotransferase increase (2% vs 2%).
Papadimitrakopoulou V, Gadgeel SM, Borghaei H, et al. First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. J Clin Oncol. 2017;35 (suppl; abstr 9094).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication